Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr 27;7(1):140.
doi: 10.1038/s41392-022-01000-3.

Vaccination versus SARS-CoV-2 Omicron: three vaccine doses win the battle

Grzegorz Maria Popowicz  1 , Krzysztof Pyrc  2 , Kamyar Hadian  3
Affiliations
Comment

Vaccination versus SARS-CoV-2 Omicron: three vaccine doses win the battle

Grzegorz Maria Popowicz et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

G.M.P., K.P., and K.H. hold a patent on inhibition of SARS-CoV-2 PLpro.

Figures

Fig. 1
Fig. 1
Two vaccine doses are not capable of neutralizing SARS-CoV-2 Omicron. Only three doses generate enough cross-reactive antibodies to neutralize Omicron
See this image and copyright information in PMC

Comment on

References

    1. Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell185, 457–466 (2022). - PMC - PubMed
    1. Carreño, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature602, 682–688 (2022). - PubMed
    1. Wratil, P. R. et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat. Med.28, 496–503 (2022). - PubMed
    1. Owen DR, et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586–1593. doi: 10.1126/science.abl4784. - DOI - PubMed
    1. Napolitano, V. et al. Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses. Cell Chem. Biol. 29, 1–11 (2022). - PMC - PubMed

Publication types